¼¼°èÀÇ ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå : ¼¼Æ÷ À¯Çüº°, Á¦Ç° À¯Çüº°, ÀûÀÀ Áúȯº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Immune Cell Engineering Market, By Cell Type, By Product, By Disease Indication, By Application, By End User, By Geography
»óǰÄÚµå : 1741494
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,254,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,728,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,898,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀåÀº 2025³â 42¾ï 3,000¸¸ ´Þ·¯, 2032³â¿¡´Â 175¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 22.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 42¾ï 3,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 22.50% 2032³â °¡Ä¡ ¿¹Ãø 175¾ï 1,000¸¸ ´Þ·¯

¸é¿ª ¼¼Æ÷ °øÇÐÀº ¾ÏÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ Áúº´ÀÇ Ä¡·á¿¡ Çõ¸íÀ» °¡Á®¿Ã ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ÃÖ±Ù Å« ÁÖ¸ñÀ» ¹Þ°í ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ¸é¿ª ¼¼Æ÷ °øÇÐÀº ¾Ï¼¼Æ÷ ¹× ±âŸ º´¿øÃ¼¸¦ Ç¥ÀûÀ¸·Î »ï¾Æ ÆÄ±«ÇÏ´Â ¸é¿ª¼¼Æ÷ÀÇ ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇØ ¸é¿ª¼¼Æ÷¸¦ Á¶ÀÛÇϰųª º¯ÇüÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. ÀÌ ½ÅÈï ºÐ¾ß´Â ¸é¿ªÇÐ, ºÐÀÚ»ý¹°ÇÐ, À¯Àü°øÇÐÀÇ ¿ø¸®¸¦ °áÇÕÇÏ¿© Çõ½ÅÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇÕ´Ï´Ù.

¸é¿ªÃ¼°è´Â ü³»ÀÇ ¿ÜºÎ ÀûÀ̳ª ºñÁ¤»óÀûÀÎ ¼¼Æ÷¸¦ ÀνÄÇϰí Á¦°ÅÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±×·¯³ª ƯÁ¤ Áúº´¿¡ ´ëÇØ¼­´Â ¸é¿ª¹ÝÀÀÀÌ ºÒÃæºÐÇϰųª È¿°ú°¡ ¾ø´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. °úÇÐÀÚµéÀº ¸é¿ª¼¼Æ÷¸¦ À¯Àü°øÇÐÀûÀ¸·Î º¯Çü½ÃÄÑ ¾Ï¼¼Æ÷¿Í °°Àº ƯÁ¤ Ç¥ÀûÀ» ÀνÄÇÏ°í °ø°ÝÇÏ´Â ´É·ÂÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀåÀº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ Áúº´ÀÇ È®»êÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´¿¡ ´ëÇÑ ±âÁ¸ Ä¡·á¹ý¿¡´Â ÇѰ谡 ÀÖ¾î Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

µÑ°, À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀüÀ¸·Î ¸é¿ª ¼¼Æ÷ °øÇÐÀÇ È¿À²¼º°ú Á¤È®¼ºÀÌ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, CRISPR/Cas9¿Í °°Àº À¯ÀüÀÚ ÆíÁý µµ±¸´Â ¸é¿ª ¼¼Æ÷ÀÇ º¯ÇüÀÌ ¿ëÀÌÇØÁ® Ä¡·á °¡´É¼ºÀÌ ³ô¾ÆÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±×·¯³ª ÇØ°áÇØ¾ß ÇÒ °úÁ¦¿Í ÀúÇØ¿äÀεµ ¸î °¡Áö Á¸ÀçÇÕ´Ï´Ù. ÁÖ¿ä °úÁ¦ Áß Çϳª´Â ¸é¿ª ¼¼Æ÷ °øÇÐ Ä¡·á¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ °³¹ß ¹× Á¦Á¶ °úÁ¤Àº º¹ÀâÇϰí Àü¹®ÀûÀÎ ½Ã¼³°ú Àü¹® Áö½ÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ ¶§¹®¿¡ ƯÈ÷ ½ÅÈï±¹¿¡¼­´Â ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ ÀÌ¿ëÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 12¿ù Á¦¾àȸ»ç ±æ¸®¾îµå »çÀ̾𽺴 ÀÓ»ó ´Ü°èÀÇ »ý¸í°øÇÐ ±â¾÷ Tmunity Therapeutics Inc.¸¦ ÀμöÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Àμö¸¦ ÅëÇØ ±æ¸®¾îµå »çÀ̾𽺴 Ç×Á¾¾ç Ȱ¼ºÀ» ³ôÀ̱â À§ÇØ ´Ù¾çÇÑ CAR T ¼¼Æ÷¿¡ Àû¿ëµÉ ¼ö ÀÖ´Â '±â°©' CAR T ±â¼ú Ç÷§ÆûÀ» Æ÷ÇÔÇÑ ÀüÀÓ»ó ¹× ÀÓ»ó ÇÁ·Î±×·¥À» È®º¸ÇÏ¿© CAR T ¼¼Æ÷ Á¦Ç°ÀÇ Á¦Á¶ °øÁ¤À» °­È­ÇÏ´Â µ¥ ±â¿©Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, ¼¼Æ÷ À¯Çüº°, 2020³â-2032³â

Á¦6Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, Á¦Ç° À¯Çüº°, 2020³â-2032³â

Á¦7Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, ÀûÀÀ Áúȯº°, 2020³â-2032³â

Á¦8Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, ¿ëµµº°, 2020³â-2032³â

Á¦9Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â

Á¦10Àå ¸é¿ª ¼¼Æ÷ °øÇÐ ½ÃÀå, Áö¿ªº°, 2020³â-2032³â

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¼½¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Immune Cell Engineering Market is estimated to be valued at USD 4.23 Bn in 2025 and is expected to reach USD 17.51 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 4.23 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 22.50% 2032 Value Projection: USD 17.51 Bn

Immune cell engineering is a field that has gained significant attention in recent years due to its potential to revolutionize the treatment of various diseases, including cancer. It involves the manipulation and modification of immune cells to enhance their ability to target and destroy cancer cells or other pathogens. This emerging field combines principles of immunology, molecular biology, and genetic engineering to develop innovative therapies.

The immune system plays a critical role in recognizing and eliminating foreign invaders or abnormal cells in the body. However, in some cases, the immune response may be insufficient or ineffective against certain diseases. By genetically modifying immune cells, scientists can enhance their ability to recognize and attack specific targets, such as cancer cells.

Market Dynamics:

The immune cell engineering market is driven by several key factors. Firstly, there is a growing prevalence of various diseases, including cancer, autoimmune disorders, and infectious diseases. As traditional treatment options for these diseases often have limitations, there is a need for innovative therapeutic approaches.

Secondly, advancements in gene-editing technologies have significantly improved the efficiency and precision of immune cell engineering. Gene-editing tools such as CRISPR/Cas9 have made it easier to modify immune cells and enhance their therapeutic potential. These technological innovations are expected to drive the growth of the immune cell engineering market.

However, there are also several challenges and restraints that need to be addressed. One of the main challenges is the high cost associated with immune cell engineering therapies. The development and manufacturing processes for these therapies are complex and require specialized facilities and expertise. This has limited the accessibility of these therapies, particularly in developing countries.

For instance, in December 2022, Gilead Sciences, Inc., a pharmaceutical company, announced the acquisition of Tmunity Therapeutics Inc., a clinical-stage biotechnology company. The acquisition provided Gilead Sciences, Inc. with preclinical and clinical programs, including an "armored" CAR T technology platform that has the potential to be applied to a variety of CAR T cells to enhance anti-tumor activity, and helps to enhance manufacturing processes for of CAR T cells product.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Immune Cell Engineering Market - Impact of Coronavirus (COVID-19) Pandemic

5. Immune Cell Engineering Market, By Cell Type, 2020-2032, (US$ Bn)

6. Immune Cell Engineering Market, By Product, 2020-2032, (US$ Bn)

7. Immune Cell Engineering Market, By Disease Indication, 2020-2032, (US$ Bn)

8. Immune Cell Engineering Market, By Application, 2020-2032, (US$ Bn)

9. Immune Cell Engineering Market, By End User, 2020-2032, (US$ Bn)

10. Immune Cell Engineering Market, By Region, 2020-2032, (US$ Bn)

11. Competitive Landscape

12. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â